Silvio Tasso, MD
Internal Medicine · Bellerose, NYNPI 1356351050
Payments from drug & device makers
Across 280 payments — averaging $24.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AstraZeneca$898
- GSK$532
- Merck$520
- Amarin Pharma, Inc.$417
- Lilly USA, LLC$364
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,788100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 38 | $1,820 |
| AstraZeneca | 38 | $898 |
| GSK | 26 | $532 |
| Merck | 24 | $520 |
| Amarin Pharma, Inc. | 16 | $417 |
| Lilly USA, LLC | 22 | $364 |
| Novo Nordisk | 12 | $318 |
| Johnson & Johnson | 21 | $278 |
| Boehringer Ingelheim | 12 | $245 |
| AbbVie(2 entities) | 13 | $231 |
| Pfizer | 10 | $169 |
| Sanofi-aventis U.S. LLC | 4 | $158 |
| Ironwood Pharmaceuticals, Inc | 8 | $132 |
| Intuity Medical Inc | 1 | $109 |
| Novartis | 5 | $90 |
| Mannkind Corporation | 3 | $55 |
| Philips North America LLC | 3 | $50 |
| Genentech USA, Inc. | 2 | $46 |
| Mylan Specialty L.p. | 2 | $41 |
| Abbott | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $40 |
| Sanofi | 2 | $35 |
| Phadia US Inc. | 2 | $27 |
| Redhill Biopharma Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| IBSA Pharma Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$989
- AIRSUPRA$158
- STEGLATRO$125
- FASENRA$125
- Otezla$125
- Vascepa$125
- AIMOVIG$123
- Prolia$118
- Pogo Automatic Blood Glucose Monitoring System$109
- SOLIQUA 100/33$100
How this compares
$6,798 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 104 | $148,003 |
| EliquisApixaban | 109 | $125,314 |
| JanuviaSitagliptin Phosphate | 102 | $121,496 |
| JanumetSitagliptin Phos/Metformin Hcl | 94 | $118,901 |
| FarxigaDapagliflozin Propanediol | 112 | $106,340 |
| JardianceEmpagliflozin | 76 | $96,671 |
| TrulicityDulaglutide | 43 | $69,676 |
| XareltoRivaroxaban | 51 | $55,008 |
| OzempicSemaglutide | 33 | $51,609 |
| Repatha SureclickEvolocumab | 39 | $41,749 |
| EntrestoSacubitril/Valsartan | 20 | $29,823 |
| VascepaIcosapent Ethyl | 64 | $29,595 |
| LinzessLinaclotide | 36 | $29,333 |
| TradjentaLinagliptin | 19 | $21,963 |
| ProliaDenosumab | 13 | $21,700 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet, Janumet Xr | $520 | $250,239209 claims |
| Lilly USA, LLCMounjaro, Trulicity | $364 | $217,678147 claims |
| PfizerEliquis | $169 | $125,314109 claims |
| Boehringer IngelheimJardiance, Tradjenta | $245 | $118,63495 claims |
| AstraZenecaFarxiga, Symbicort | $898 | $110,420123 claims |
| Johnson & JohnsonXarelto | $278 | $55,00851 claims |
| Novo NordiskOzempic | $318 | $51,60933 claims |
| AbbVieLinzess, Synthroid | $231 | $31,65066 claims |
| NovartisEntresto | $90 | $29,82320 claims |
| AmgenProlia | $1,820 | $21,70013 claims |
| GSKTrelegy Ellipta | $532 | $15,96326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bellerose
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.